Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 20/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14877427 | 0.99 | CASR (0.67) | CASR | |
| SCHEMBL6005143 | 0.99 | CASR (0.67) | CASR | |
| SCHEMBL176931 | 0.88 | CASR (0.54) | CASR | |
| SCHEMBL14471566 | 0.87 | CASR (0.64) | CASR | |
| SCHEMBL14471538 | 0.86 | CASR (0.69) | CASR | |
| SCHEMBL176877 | 0.84 | CASR (0.51) | CASR | |
| SCHEMBL14471571 | 0.84 | CASR (0.66) | CASR | |
| SCHEMBL14471569 | 0.84 | CASR (0.66) | CASR | |
| SCHEMBL18469096 | 0.84 | CASR (0.66) | CASR | |
| SCHEMBL14471728 | 0.84 | CASR (0.63) | CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2345636-B1 | CASR AGONIST | AJINOMOTO KK (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-9174932-B2 | CaSR agonists | AJINOMOTO CO., INC. (JP) | 2015-11-03 | — | — | US | disclosed |
| US-20140303122-A1 | CASR AGONISTS | AJINOMOTO CO., INC. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8796485-B2 | CaSR agonists | AJINOMOTO CO., INC. (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20110251418-A1 | CASR AGONISTS | AJINOMOTO CO., INC. (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2345636-A1 | CASR AGONIST | Ajinomoto Co., Inc. (JP) | 2011-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303122-A1 | CASR AGONISTS | CASR, GIPR, GRIK5 | CASR 1/4885 |
| US-20110251418-A1 | CASR AGONISTS | CASR, GIPR, GRIK5 | CASR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.